BioSpace - Epizyme News, Search Jobs, Events

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

Search the Site

Job Seekers: Register | Login Employers: Register | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

..

Epizyme

400 Technology Square
4th Floor
Cambridge Massachusetts 02139 U.S.A.
Phone: 617-500-7240 Fax: 617-349-0707

Epizyme is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers. We systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found and then design small molecule therapeutics to inhibit the oncogene. The clinical development plan for each of our product candidates is directed towards patients with a particular genetically defined cancer. Our approach is part of a broader trend towards personalized therapeutics based on first identifying the underlying cause of a disease affecting specific patient populations, applying rational drug design tools to create a therapeutic to bind with a molecular target in the identified disease pathway and using a companion diagnostic to select the right patients for treatment.

We have built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic. When Epizyme was founded, we recognized that the HMT class of enzymes might contain many potential oncogenes and, therefore, presented the opportunity to discover, develop and commercialize multiple personalized therapeutics.

We have prioritized 20 HMTs as attractive targets for personalized therapeutics based on their oncogenic potential. Our two most advanced therapeutic product programs target the HMTs DOT1L (for the treatment of mixed lineage leukemia, or MLL-r) and EZH2 (for a genetically defined subtype of non-Hodgkin lymphoma). We believe that our ongoing Phase 1 study for EPZ-5676, targeting DOT1L, is the first clinical trial of an HMT inhibitor. We expect to initiate a Phase 1/2 clinical trial of EPZ-6438 targeting EZH2 in 2Q 2013.

We were founded in 2007 and are led by a management team with extensive experience in the pharmaceutical industry. We have entered into therapeutic collaborations with Celgene, Eisai and Glaxo Group Limited (an affiliate of GlaxoSmithKline), or GSK, that have provided us with approximately $120 million in non-equity funding through March 31, 2013. As of March 31, 2012, we had $85 million in cash and cash equivalents.

Key Statistics

Email: Contact@Epizyme.com
Ownership: Public

Web Site: Epizyme
Employees: 66
Symbol: EPZM

Industry
Biopharmaceutical

Segment
R&D with Clinical Development

Company News

Epizyme (EPZM) Announces 2013 Operating And Financial Results And Provides 2014 Guidance 2/28/2014 6:12:48 AM More...

Epizyme (EPZM) Achieves Lead Candidate Selection Milestone In GlaxoSmithKline (GSK) Collaboration, Earning $2 Million Milestone 2/27/2014 9:58:44 AM More...

Epizyme (EPZM) Announces Publication Of Preclinical Data Demonstrating Clinical Candidate EPZ-6438 As Potent And Selective Inhibitor Of EZH2 In Genetically Defined Non-Hodgkin Lymphoma 2/21/2014 9:12:13 AM More...

Epizyme (EPZM) To Report Fourth Quarter And Year-End 2013 Financial Results On February 27, 2014 2/20/2014 6:30:05 AM More...

Epizyme (EPZM) Announces Exercise Of Underwriters' Option To Purchase Additional Shares Of Common Stock 2/11/2014 10:17:12 AM More...

Epizyme (EPZM) To Present At Upcoming Conferences In February 2/7/2014 6:26:48 AM More...

Epizyme (EPZM) Announces Pricing Of Public Offering Of Common Stock 2/5/2014 8:00:56 AM More...

Epizyme (EPZM) Announces Proposed Public Offering Of Common Stock 2/3/2014 10:49:04 AM More...

Epizyme (EPZM) Struts Back To Wall Street, Plans $140 Million Raise 1/27/2014 8:06:02 AM More...

Epizyme (EPZM) Pockets $25 Million From Celgene Corporation (CELG) As Leukemia Drug, EPZ-5676 DOT1L Inhibitor, Performs Well In Phase 1 Trial; EPZM Stock Soars +75.56% At Market Close (January 7, 2014) 1/7/2014 6:52:45 AM More...

1

//-->